All In Biotech

Drug Trial Radar · NCT02660034

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

229

Actual

Start

Feb 2, 2016

Primary completion

Sep 9, 2020

Study completion Sep 9, 2020

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
Collaborators
Myriad Genetic Laboratories, Inc.
First posted
Jan 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial studied the safety, pharmacokinetics, and antitumor activity of the anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) BGB-A317 (tislelizumab) in combination with the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor BGB-290 (pamiparib) in participants with advanced solid tumors.

Conditions

  • Solid Tumors

Interventions

  • TislelizumabBiological

  • PamiparibDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number Of Participants Experiencing Adverse Events (AEs)Time frame: From Day 1 up to 4 years and 7 months
  2. Part A: Number Of Participants Experiencing Dose-limiting Toxicity (DLT)Time frame: 21 days following the first dose of tislelizumab and pamiparib in Cycle 1
  3. Part B: Objective Response Rate (ORR)Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
  4. Part B: Progression-free Survival (PFS)Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
  5. Part B: Duration Of Response (DOR)Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
  6. Part B: Disease Control Rate (DCR)Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
  7. Part B: Clinical Benefit Rate (CBR)Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
  8. Part B: Overall Survival (OS)Time frame: From Day 1 Every 3 months following completion or discontinuation of the treatment (up to 4 years and 7 months)

Locations

29 sites in 6 countries. Site status is shown where the registry gives one.

  • Pinnacle Oncology Hematology

    Scottsdale, Arizona

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Texas Oncology

    Dallas, Texas

  • Texas Oncology

    Tyler, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • The Canberra Hospital

    Garran, Australian Capital Territory, Australia

  • Mid North Coast Cancer Institute

    Coffs Harbour, New South Wales, Australia

  • Calvary Mater Newcastle

    Newcastle, New South Wales, Australia

  • Westmead Hospital

    Parramatta, New South Wales, Australia

  • Prince of Wales

    Randwick, New South Wales, Australia

  • Northern Cancer Institute

    St Leonards, New South Wales, Australia

  • Icon Cancer Care

    Brisbane, Queensland, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Linear Clinical Research Ltd

    Nedlands, Western Australia, Australia

  • Institut Gustave Roussy

    Paris, France

  • Centre Eugene Marquis

    Rennes, France

  • Auckland City Hospital

    Auckland, New Zealand

  • Capital and Coast District Health Board

    Wellington, New Zealand

  • Hospital Universitario Vall d'Hebrón

    Barcelona, Spain

  • Hospital Clínico Universitario de Valencia

    Valencia, Spain

  • Sarah Cannon Research Institute

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.